Stockscreener 앱 받기
11.49
1.96%
-0.23
시간 외 거래:
11.71
0.22
+1.91%
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
Can LENZ Therapeutics Inc. be the next market leader2026 Big Picture & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026 - The Manila Times
IPO Launch: Is LENZ Therapeutics Inc affected by consumer sentimentMarket Rally & AI Driven Stock Movement Reports - baoquankhu1.vn
693,044 Shares in LENZ Therapeutics, Inc. $LENZ Acquired by First Light Asset Management LLC - MarketBeat
LENZ Therapeutics, Inc. $LENZ is Ally Bridge Group NY LLC's 7th Largest Position - MarketBeat
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia - marketscreener.com
Performance Recap: Can LENZ Therapeutics Inc reach all time highs this year2026 Historical Comparison & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
LENZ Therapeutics Projected to Post Earnings on WednesdayDel Mar Today - National Today
William Blair Maintains Outperform on LENZ Therapeutics, Inc (LENZ) March 10 2026 - Meyka
LENZ Therapeutics (LENZ) Projected to Post Earnings on Wednesday - MarketBeat
LENZ submits marketing application for presbyopia drug in Europe - Investing.com South Africa
William Blair reiterates Lenz Therapeutics stock rating on VIZZ potential By Investing.com - Investing.com Canada
LENZ submits marketing application for presbyopia drug in Europe By Investing.com - Investing.com Australia
LENZ: Rapidly growing prescriber base and strong refill rates highlight successful launch momentum - TradingView
LENZ: Strong launch for a new presbyopia eye drop, with rapid adoption and robust safety profile - TradingView
William Blair reiterates Lenz Therapeutics stock rating on VIZZ potential - Investing.com
LENZ Therapeutics Submits Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia - marketscreener.com
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia - LENZ Therapeutics
New eye drop for age-related blurry vision heads to EU review - Stock Titan
Tyro Capital Management LLC Makes New $4.69 Million Investment in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Lenz plunges after adverse event report on eye therapy - MSN
Aug Sentiment: Is LENZ Therapeutics Inc a strong candidate for buy and hold2026 Price Momentum & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Market Pulse: Why is LENZ Therapeutics Inc stock going upMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Presbyopia Pipeline 2026: 10+ Companies, 10+ Emerging Therapies, and 3 Key FDA NDA Milestones Driving the Future of Vision Care, analyses DelveInsight - StreetInsider
LENZ: Strong launch momentum for a new presbyopia eye drop, with robust efficacy and market uptake - TradingView
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Should You Buy LENZ Therapeutics Inc (LENZ) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
LENZ Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Bearish Setup: What are LENZ Therapeutics Incs recent SEC filings showingMarket Activity Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
LENZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Versant Venture Management LLC Buys Shares of 2,656,888 LENZ Therapeutics, Inc. $LENZ - MarketBeat
LENZ Therapeutics to Present at Upcoming Investor Conferences - LENZ Therapeutics
Presbyopia eye-drop firm LENZ lines up two investor conferences - Stock Titan
Risk Check: Can LENZ Therapeutics Inc sustain its profitabilityGold Moves & High Accuracy Swing Trade Signals - baoquankhu1.vn
LENZ Therapeutics (NASDAQ:LENZ) Rating Lowered to Sell at Wall Street Zen - MarketBeat
What’s the beta of LENZ Therapeutics Inc. stockQuarterly Profit Review & Breakout Confirmation Trade Signals - mfd.ru
Breakout Move: What are LENZ Therapeutics Incs recent SEC filings showingWeekly Gains Summary & High Yield Equity Trading Tips - baoquankhu1.vn
Weekly Earnings: Can LENZ Therapeutics Inc reach all time highs this yearMarket Trend Review & Safe Entry Zone Tips - baoquankhu1.vn
LENZ Therapeutics, Inc. $LENZ Shares Acquired by Skandinaviska Enskilda Banken AB publ - MarketBeat
Ridgeback exits Lenz Therapeutics (LENZ) with 0% reported ownership stake - Stock Titan
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Decreases By 16.8% - MarketBeat
How LENZ Therapeutics Inc. stock compares to market leaders2025 EndofYear Setup & Fast Gain Stock Trading Tips - mfd.ru
LENZ Therapeutics (LENZ) Stock Analysis: Eyeing A 295% Upside In The Biotech Arena - DirectorsTalk Interviews
Analyst Upgrade: Can LENZ Therapeutics Inc disrupt its industryNew Guidance & Consistent Income Trade Recommendations - baoquankhu1.vn
Why is LENZ Therapeutics Inc. stock going upWeekly Stock Report & Reliable Price Action Trade Plans - mfd.ru
Fund Flows: What is the cash position of LENZ Therapeutics IncEarnings Recap Report & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Can LENZ Therapeutics Inc. benefit from deglobalizationJuly 2025 Momentum & Low Risk Growth Stock Ideas - mfd.ru
Is LENZ Therapeutics Inc. stock a value trapBreakout Watch & Advanced Technical Signal Analysis - mfd.ru
Is LENZ Therapeutics Inc. benefiting from interest rate changesWeekly Trading Summary & Low Risk High Win Rate Picks - mfd.ru
Guidance Update: Can LENZ Therapeutics Inc be the next market leaderEarnings Overview Summary & Low Risk Entry Point Tips - baoquankhu1.vn
No Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA Nod - MSN
Investment Recap: Why is LENZ Therapeutics Inc stock going upQuarterly Profit Review & Growth Focused Entry Point Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO), LENZ Therapeutics (LENZ) and Amgen (AMGN) - The Globe and Mail
Lenz Therapeutics price target lowered to $35 from $52 at BofA - TipRanks
LENZ Therapeutics stock price target lowered to $35 at BofA on slower ramp - Investing.com Canada
1.20%
0.06%
자본화:
|
볼륨(24시간):